Molecular Function
Neomorph Secures $1.6 Billion Deal with AbbVie to Develop Molecular Glue Degraders for Oncology and Immunology
Neomorph, AbbVie, molecular glue degraders, oncology, immunology, protein degradation, drug development, biotechnology, pharmaceutical partnership.
Neomorph Secures Third Major Collaboration with AbbVie for Molecular Glue Degraders Worth Up to $1.64 Billion
Neomorph, AbbVie, molecular glue degraders, protein degradation, oncology, immunology, biotechnology, pharmaceutical collaboration
Advancements in BTK Inhibitors for Chronic Lymphocytic Leukemia: A Comparative Analysis of AstraZeneca, Eli Lilly, and BeiGene Therapies
BTK inhibitors, Chronic Lymphocytic Leukemia (CLL), AstraZeneca, Eli Lilly, BeiGene, Acalabrutinib, Ibrutinib, Zanubrutinib, Pirtobrutinib, Nemtabrutinib, Fixed-duration therapy, Continuous therapy, Efficacy, Safety
Kymera Therapeutics Shifts Focus to Immunology, Scaling Back Oncology Efforts
Kymera Therapeutics, Immunology, Oncology, Targeted Protein Degradation, IRAK4, STAT6, TYK2
Novartis Secures FDA Approval for Scemblix as First-Line Treatment for Newly Diagnosed CML, Anticipates $3B in Peak Sales
Novartis, Scemblix, FDA Approval, First-Line Treatment, CML, Chronic Myeloid Leukemia, ASC4FIRST Trial, Tyrosine Kinase Inhibitors, STAMP Inhibitor
Novartis and Monte Rosa Collaborate on $2.2B Molecular Glue Degrader Alliance
Novartis, Monte Rosa, molecular glue degraders, biopharma collaboration, protein degradation, oncology, neurological diseases
Novartis Invests $150M in Monte Rosa’s Molecular Glue Technology for Autoimmune Diseases
Novartis, Monte Rosa, Molecular Glue, Protein Degradation, Autoimmune Diseases, MRT-6160, VAV1-degrader, Biotech Collaboration
Booster Therapeutics Launches with $15 Million Funding to Pioneer Proteasome Activator Therapies for Neurodegenerative Diseases
Proteasome activator therapies, Neurodegenerative diseases, Booster Therapeutics, Novo Holdings, Apollo Health Ventures, 20S proteasome, Protein degradation, Neurodegeneration
AstraZeneca Acquires Pinetree’s EGFR Degrader for $45 Million Upfront
AstraZeneca, Pinetree Therapeutics, EGFR degrader, protein degrader, oncology, licensing agreement, milestone payments, royalties, targeted protein degradation, molecular glues, cancer treatment
Syntis Bio Launches Revolutionary Oral Therapy to Mimic Weight-Loss Surgery
Syntis Bio, weight-loss surgery, oral therapy, obesity, diabetes, rare diseases, SYNT-101, gastric bypass surgery, small intestine, metabolic control, digestion, drug absorption.